Bachurski, Patryk, Gabriela Chmiel, Paweł Kalinowski, Maja Międlar, Martyna Muda, Szymon Pacek, Elisabetta Pierzga, Karol Wiśniewski, Paweł Witkowski, and Bartosz Zarański. “Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025)”. Quality in Sport 51 (January 31, 2026): 68252. Accessed February 1, 2026. https://apcz.umk.pl/QS/article/view/68252.